Anti-opioid mAb patent, University of Minnesota, 7th Apr

The USPTO granted patent US12594330B2 to the Regents of the University of Minnesota covering opioid-specific monoclonal antibodies (mAbs), methods of manufacturing those antibodies, and therapeutic uses. The patent claims cover treatment of opioid use disorder, neonatal opioid withdrawal syndrome, and opioid overdose prevention and reversal. The invention also extends to detection of opioids in screening, diagnostic, or forensic assays.

Methods of treating psoriasis with secukinumab

The USPTO granted Patent US12594331B2 to Novartis AG on April 7, 2026, covering methods of treating psoriasis using secukinumab, an IL-17 antagonist antibody. The patent contains 16 claims directed to therapeutic regimens employing the drug for psoriasis treatment. This grant provides Novartis with exclusive intellectual property rights over this specific treatment methodology in the United States.

Platinum-based drug/photosensitizer-loaded protein nanoparticle patent granted to Soochow University

USPTO granted patent US12594335B2 to Soochow University on April 7, 2026, covering platinum-based drug/photosensitizer-loaded protein nanoparticles for combined chemotherapy and photodynamic tumor treatment. The invention includes 6 claims for nanoparticles with platinum-based drugs and photosensitizers encapsulated in protein carriers. Filing date was July 24, 2020, with application number 18012295.

Human Serum Albumin in Formulations

USPTO granted patent US12594337B2 to Regeneron Pharmaceuticals, Inc. covering human serum albumin formulations for reducing fatty acid particle formation in drug products, particularly antibody drug formulations. The patent contains 14 claims and was filed December 30, 2021.

Lipid nanoparticle delivery compositions for therapeutic agents

USPTO granted ModernaTX patent US12595226B2 for novel lipid nanoparticles and compositions for intracellular delivery of therapeutic agents. The patent covers carbonate-containing lipid compounds and compositions for delivering therapeutic and prophylactic agents such as RNA to mammalian cells. The patent contains 25 claims and names five inventors.

Lamotrigine hydrate crystal form, preparation method, and composition

The USPTO granted Patent US12595237B2 to Shanghai Aucta Pharmaceuticals Co., Ltd. for a crystalline form of lamotrigine hydrate (Form A), its method of preparation, and pharmaceutical compositions containing it. The patent contains 13 claims and is classified under CPC code A61K 31/53, covering the specific solid-state form of this antiepileptic drug compound.

ERK Modulators Patent - Gen1E Lifesciences, Cancer Treatment

USPTO granted patent US12595243B2 to GEn1E Lifesciences Inc. covering modulators of extracellular signal-regulated kinase (ERK) for treating cancer and pulmonary diseases. The patent includes 17 claims on the chemical compounds and pharmaceutical compositions. Inventors are Adam Galan, Ritu Lal, and Chakk Ramesha.

Companies (Amendment) Regulations 2026 - Extension to LLPs and VCCs

The Singapore Ministry of Finance published the Companies (Amendment) Regulations 2026 (S 205), extending disqualification provisions currently applicable to company directors under Form 45 to also cover Limited Liability Partnerships (LLPs) under the LLP Act 2005 and Variable Capital Companies (VCCs) under the VCC Act 2018. The amendments add cross-references to relevant sections of the LLP Act and VCC Act and take effect on 6 May 2026.

Companies (Filing of Documents) (Amendment) Regulations 2026

The Ministry of Finance, Singapore has issued the Companies (Filing of Documents) (Amendment) Regulations 2026 (S 203), amending the Companies (Filing of Documents) Regulations (Rg 7). The amendments remove references to section 12(2)(a) of the Companies Act 1967 from regulations 7A and 7B, limiting the applicable provision to section 12(2)(b) only. The regulations were made on 3 April 2026 and take effect on 6 May 2026.

Companies (Revision of Defective Financial Statements) (Amendment) Regulations 2026

The Singapore Ministry of Finance has amended the Companies (Revision of Defective Financial Statements, or Consolidated Financial Statements or Balance-sheet) Regulations 2018 via Subsidiary Legislation No. S 206. The amendment modifies regulation 4(4)(b) to clarify that any Minister's order under section 201(15) of the Companies Act substituting alternative accounting standards applies to revised financial statements. The amendments take effect on 6 May 2026.